Bellerophon announces top-line data from phase 3 rebuild clinical trial of inopulse® for treatment of fibrotic interstitial lung disease

Warren, n.j., june 05, 2023 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal phase 3 rebuild clinical trial evaluating the safety and efficacy of inopulse® for the treatment of fibrotic interstitial lung disease (fild).
BLPH Ratings Summary
BLPH Quant Ranking